The inspection, conducted between August 11-13, 2025, was a pre-approval inspection (PAI) for three products and also covered general current Good Manufacturing Practices (cGMP). The company said the inspection concluded with no observations, indicating full compliance with regulatory requirements.
First quarter results
The company reported a 3.3% growth in its net profit to ₹1,467 crore, which was also aided by a forex gain of ₹57 crore. The base quarter had a forex loss of ₹25 crore. The net profit figure was also higher than the CNBC-TV18 poll of ₹1,211.6 crore.
Also Read: Zydus Lifesciences Q3 Results: US formulation sales near $300 million, forex gains aid profit
Revenue for the quarter increased by 6% from last year to ₹6,574 crore, which is also higher than the CNBC-TV18 poll estimate of ₹6,350 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) for the quarter remained flat at ₹2,089 crore, while analysts were working with a number of ₹1,879.3 crore.
EBITDA margins, though, narrowed by nearly 200 basis points to 31.8% from 33.6% last year. Analysts were expecting the margin figure to be at 29.6%. US sales for the quarter remained largely flat from last year and increased 2.5% from the March quarter to $372 million.
Also Read: Zydus Lifesciences gets first Canadian nod for smoking deterrent varenicline tablets
“We remain firmly on track to achieve our FY2026 aspirations and are excited about the upcoming developments on the innovation front, which we believe will open up new avenues for sustainable growth,” Sharvil Patel, Managing Director of Zydus Life, was quoted as saying.
Shares of Zydus Lifesciences Ltd ended at ₹989.05, up by ₹32.95 or 3.45%, on the BSE today (August 13).
(Edited by : Shoma Bhattacharjee)
